NCT03177603View on ClinicalTrials.gov

A Dose-escalation Study in Subjects With Pulmonary Arterial Hypertension (PAH)

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

February 21, 2018

Primary Completion Date

May 7, 2019

Study Completion Date

May 7, 2019

Conditions
Hypertension, Pulmonary
Interventions
DRUG

GSK2586881

GSK2586881 is a clear colorless liquid for IV infusion over 3- 5 minutes and will be administered a maximum dose of 0.8 mg/kg.

Trial Locations (8)

14050

GSK Investigational Site, Berlin

15213

GSK Investigational Site, Pittsburgh

28041

GSK Investigational Site, Madrid

50937

GSK Investigational Site, Cologne

69126

GSK Investigational Site, Heidelberg

75390-8550

GSK Investigational Site, Dallas

01307

GSK Investigational Site, Dresden

08035

GSK Investigational Site, Barcelona

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT03177603 - A Dose-escalation Study in Subjects With Pulmonary Arterial Hypertension (PAH) | Biotech Hunter | Biotech Hunter